![Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial - The Lancet Infectious Diseases Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/ff3fcd42-3af8-4f3a-bd21-0978ffae8520/gr1.jpg)
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial - The Lancet Infectious Diseases
![Financial Times on X: "Stéphane Bancel said scientists were worried because 32 of the 50 mutations in the Omicron variant are on the spike protein, which current vaccines focus on to boost Financial Times on X: "Stéphane Bancel said scientists were worried because 32 of the 50 mutations in the Omicron variant are on the spike protein, which current vaccines focus on to boost](https://pbs.twimg.com/media/FFcDEVmXsAIPlxj.jpg:large)
Financial Times on X: "Stéphane Bancel said scientists were worried because 32 of the 50 mutations in the Omicron variant are on the spike protein, which current vaccines focus on to boost
![Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain | Nature Communications Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-023-37128-1/MediaObjects/41467_2023_37128_Fig1_HTML.png)
Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain | Nature Communications
![Frontiers | Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months Frontiers | Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months](https://www.frontiersin.org/files/Articles/1152522/fimmu-14-1152522-HTML/image_m/fimmu-14-1152522-g001.jpg)
Frontiers | Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months
![Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy - eBioMedicine Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy - eBioMedicine](https://www.thelancet.com/cms/attachment/2b318701-6e1d-45b8-a61e-79e7d75d5cd0/gr1.jpg)
Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy - eBioMedicine
![Boost spike after throttle closure? Log attached. - JB4tech.com - International Turbo Tuning Discussion Boost spike after throttle closure? Log attached. - JB4tech.com - International Turbo Tuning Discussion](https://i.imgur.com/lhC0jvI.png)
Boost spike after throttle closure? Log attached. - JB4tech.com - International Turbo Tuning Discussion
![Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2 - ScienceDirect Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1931312822003523-fx1.jpg)
Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2 - ScienceDirect
![Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/asset/d5f2c9cf-7564-4323-ad2c-c492b2547a6d/gr1.jpg)
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe
![A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines - ScienceDirect A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2666379122003482-fx1.jpg)